EFFEKTIVNOST' KOMBINIROVANNOY ANTIGIPERTENZIVNOY TERAPII ZhENShchIN S ARTERIAL'NOY GIPERTENZIEY I IShEMIChESKOY BOLEZN'Yu SERDTsA, VKLYuChAYuShchEY RAZLIChNYE BLOKATORY RENIN-ANGIOTENZINOVOY SISTEMY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the results of the study involving 100 women with arterial hypertension (AH) and stable coronary heart disease (CAD); the study was aimed to the evaluation of antihypertensive efficacy of ACE inhibitor zofenopril and angiotensin II receptor blocker valsartan using once a day and twice a day administration. Follow-up period was 24 weeks. It has been shown that combined antihypertensive therapy based on administration of valsartan twice a day may have advantages over the use of zofenopril in women with a combination of arterial hypertension and stable coronary artery disease.

全文:

受限制的访问

参考

  1. Wyskida K., Jura-Szoltys E., Smertka M., et al. Factors that favor the occurrence of cough in patients treated with ramipril-a pharmacoepidemiological study. Med Sci Monit. 2012; 18(9): 21-8.
  2. Dahlof B, Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan intervention for Endpoint reduction in hypertension study (LiFE): A randomized trial against atenolol. Lancet. 2002; 359: 995-1003.
  3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5-26.
  4. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2008; 7(6). Приложение 4.
  5. Capri Workshop Group. Hormones and cardiovascular health in women. Human Report Update. 2006; 12: 483-97.
  6. Рекомендации по снижению общего риска развития заболеваний и осложнений у женщин. М., 2010.
  7. Reckelhoff J.F. Basic research into the mechanisms responsible for postmenopausal hypertension. int. J. Clin. Pract. 2004; 58(suppl. 139): 13-9.
  8. Dzan V., Sasamura H., Hein L. Heterogeneity of angiotensin synthetic pathways and subtypes: Physiological and pharmacological implication.J. Hypertension. 1993; 11: 13-8.
  9. Urata H., Boehm K.D., Philip A. et al. Cellular localization and regional dis-tribution of an angiotensin ii-forming chymase in the heart. J Clin invest. 1993; 91: 1269-81.
  10. Nishimura H., Hoffman S., Baltatu O. et al. Angiotensin i converting enzyme and chymase in cardiovascular tissues. Kidney int. 1996; 49: 18-23.
  11. Denton K.M., Hilliard L.M., Tare М. Sex-Related Differences in Hypertension: Seek and Ye Shall Find. Hypertension. 2013; 62: 674-77.
  12. Brown R.D., Hilliard L.M., Head G.A., et al. Sex differences in the pressor and tubuloglomerular feedback response to angiotensin ii. Hypertension. 2012; 59: 129-35.
  13. McCarthy C.A., Widdop R.E., Denton K.M., Jones E.S. Update on the angiotensin AT(2) receptor. Curr. Hypertens Rep. 2013; 15: 25-30.
  14. Скибицкий В.В., Медведева Ю.Н., Шухардина Е.Л. и др. Факторы риска и структура кардиоваскулярной патологии у женщин в климаксе различного генеза. Проблемы женского здоровья. 2007; 3(2): 21-8.
  15. Hermida R.C., Ayala D.E., Mojon A., et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing Chronobiol int. 2011; 28(7): 601-10.
  16. Yoshida H., Shimizu M., Ikewaki K. et al. Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study. J. Hypertens. 2010; 28(6): 1150-57.
  17. Mazzolai L., Daven V., Centeno C., Nussberger J., Brunner H.R., Burnier M. Assessment of angiotensin ii receptor blockade in humans using a standardized angiotensin ii receptor-binding assay. Am. J. Hypertens. 1999; 12(12 Pt1-2): 1201-08.
  18. Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. int J. Clin. Pract.2006; 60; 3: 315-20.
  19. Ando H., Ushijima K., Hosohata K., et al. Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. Br. J. Clin. Pharmacol. 2013; 75(2): 415-22.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##